维持性血液透析(MHD)患者高钾血症管理的研究进展

孙 佐雅, 孙 懿
首都医科大学附属复兴医院肾内科

摘要

目前维持性血液透析(MHD)是慢性肾衰竭患者延长生存时间，提高生活质量较常见的治疗方法，而严重电解质紊乱——高钾血症是慢性肾功能衰竭患者中最多见且威胁生命的并发症。对于MHD患者来说，体内大部分的钾通过透析排出，更易受到多种因素的影响。目前在临床工作中，有多种对MHD患者高钾血症的干预措施。本文将对MHD患者高钾血症的发生原因及高钾血症患者临床及生活中的管理研究进展进行综述。

关键词

维持性血液透析（Maintenancehemodialysis;MHD）；高钾血症；干预；管理

参考

[1]Kovesdy CP.Management of hyperkalaemia in chronic Kidney disease [J].Nat Rev Nephrol,2014,10(11)：653-662.

[2]Kovesdy CP.Management of hyperkalemia: an update for the internist [J].Am J Med,2015,128（12）：1281-1287.

[3]Sacchetti A, Stuccio N,Panebianco P,et al.ED hemodialysis for treatment of renal failure emergencies[J].Am J Emerg Med,1999,17(3):305-307.

[4] 陈圣娟 . 健康教育对 MHD 高钾血症的干预作用 [J]. 当 代临床医刊，2015,28(6):1780-1781.

[5] 应鹏翔，朱金秀，谭学瑞 . 高钾血症的心电图表现以及 研究进展［J］. 实用心电学杂志， 2019,28(1):61-64.

[6]Mount DB. Clinical manifestations of hyperkalemia in adults. In：Basow DS， editor.UpToDate.Waltham(MA):UpToDate;2013.

[7]Mushiyakh Y, Dangaria H，Qavi S, et al. Treatment and pathogenesis of acute hyperkalemia．J Community Hosp Intern Med Perspect,2012 Jan 26;1(4).

[8]Mount DB，Zandi—Nejad K．Disorders of potassium balance. Brenner & Rector’s the kidney,2004:997 ～ 1040.

[9] 葛均波，徐永健，王辰 . 内科学 [M]. 北京：人民卫生出 版社 ,2018:520.

[10] 罗莉，张杰，李婵，等 . 个体化健康教育在血液透析 高钾患者中的应用 [J]. 北京医学 ,2016,38(2):175-176.

[11] 马丽洁，周亦伦，孙芳，等 .MHD 患者高钾血症的影 响因素 [J]. 首都医科大学学报，2009,30(2):150-153.

[12]Miklos Z. Molnar, Kamyar Kalantar-Zadeh, Evan H. Lott, Jun Ling Lu, et al.ACEI and ARB and Mortality in Chronic Kidney Disease.Journal of the American College of Cardiology,2014:650-658.

[13] 陈竹青，张荣国 .MHD 并发高钾血症 28 例原因分析 [J]. 中国基层医药，2014,21（1）：139-140.

[14]Knoll GA，Hun RC，Schyal’A，et al.Renin- angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients[J].Am J Med,2002，112(2)：110-114.

[15]Jesse Theisen-Toupal.Hypokalemia and Hyperkalemia. Review Article Hospital Medicine Clinics,2015,4(1):34-50.

[16]C.M.Kieffer,P.W.Abel. Hyperkalemia. Reference Modulein Biomedical Sciences,2014.

[17]Muschart X , Boulouffe C , Jamart J , et al. A determination of the current causes of hyperkalaemia and whether they have changed over the past 25 years[J]. acta clinica belgica, 2014, 69(4):280-284.

[18] 李勤 . 慢性肾脏病患者发生高钾血症的相关因素 [J]. 当 代医学 ,2012,18(21):76-77.

[19]SANGHAVI S, WHITING S, URIBARRI J. Potassium balance in dialysis patients [J]. Semin Dial,2013,26(5):597-603.

[20] 周凌辉，裴娟，侯香华，等 . 单纯低钾饮食和低钾饮 食联合小剂量聚苯乙烯磺酸钙治疗 MHD 患者高钾血症的疗效 比较 [J]. 中国全科医学，2016,19（27）：3351-3355.

[21]JADOUL M, THUMMA J, FULLER D S, et al. Modifiable practices associated with sudden death among hemodialysis patients in the dialysis outcomes and practice patterns study[J]. Clin J Am Soc Nephrol,2012,7(5):765-774.

[22]PUN P H, LEHRICH R W, HONEYCUTT E F, et al. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics [J]. Kidney Int, 2011,79(2):218-227.

[23]MUNOZ R I, MONTENEGRO J, SALCEDO A, et al.Effect of acetate-free biofiltration with a potassium-profiled dialysate on the control of cardiac arrhythmias in patients at risk: a pilot study [J]. Hemodial Int,2008,12(1):108-113.

[24] 吴春霞，黄玲 . 血透导管功能障碍及其预防 [J].Internal Medicine，2019,14（5）：574-576.

[25] 钱淑萍． 尿激酶溶栓在留置血液透析长期导管中的应 用与效果评析［J］. 中国继续医学教育，2018，10（4）：116- 117.

[26]NELMS M N, SUCHER K P, LACEY K, et al. Nutrition Therapy and Pathophysiology [M].2nd Edition Nelms: Cengage Learning, 2010.

[27]PANI A, FLORIS M, ROSNER MH, et al. Hyperkalemia in hemodialysis patients[J]. Semin Dial, 2014,27(6):571-576.

[28]Filiopoulos V, Koutis I, Trompouki S, et al. Lanthanum Carbonate Versus Sevelamer Hydrochloride: Improvement of Metabolic Acidosis and Hyperkalemia in Hemodialysis Patients[J]. Therapeutic Apheresis & Dialysis,2011,15(1):20-27.

[29] 吴丽芬，李淑艳，叶芸，等 . 仿真食物模型对 MHD 患 者血钾管理的效果研究 [J]. 浙江医学教育 ,2019,18(03):32-34.

[30]CHAABAN A, ABOUCHACRA S, GEBRAN N, et al. Potassium binders in hemodialysis patients: a friend or foe? [J].Ren Fail,2013,35(2):185-188.

[31]Rosano GMC, Spoletini I, Agewall S.Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate[J].Eur Heart J Suppl,2019,21(Suppl A):A28-A33.

[32]Palmer BF.Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis[J].Mayo Clin Proc,2020,95(2):339-354.

[33]Sterns RH, Rojas M, Bernstein P, et al. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?[J]. J Am Soc Nephrol,2010,21(5):733-735.

[34]Li T，Vijayan A. Insulin for the treatment of hyperkalemia： a double-edged sword?[J]. Clin Kidney J,2014,7(3):239-241.

[35]Bushinsky DA，Williams GH，Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia[J]. Kidney Int,2015,88(6):1427-1433.

[36]Stavros F，Yang A，Leon A, et al. Characterization of structure and function of ZS-9，a K+ selective ion trap[J]. PLoS One,2014,9(12):e114686.

[37]Kosiborod M，Rasmussen HS，Lavin P，et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia：the HARMONIZE randomized clinical trial[J]. JAMA，2014，312（21）：2223- 2233.

[38]Packham DK, Rasmussen HS, Lavin PT,et al. Sodium zirconium cyclosilicate in hyperkalemia[J].N Engl J Med, 2015,372(3):222-231.

[39]Kovesdy,Csaba P.Management of hyperkalemia：an update for the internist[J]. Am J Med，2015,128(12):1281-1287.

[40]The Royal Children’s Hospital Melbourne. Resuscitation clinical practical guidelines[EB/OL].(2016-03-02)[2016-04- 12].http://www.rch.org.au/clinicalguide/guideline_index/ Hyperkalaemia/.